Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881

Status	RECRUITING
Phase	Phase 3
Sponsor	Pharvaris Netherlands B.V.
Enrollment	170 participants

Key Eligibility Criteria

Inclusion (7)

- Provision of the signed ICF by the participant and/or legally designated representative.
- Male or female, aged e12 years at the time of providing written informed consent/assent.
- Diagnosis of hereditary angioedema (HAE)
- For participants that did not participate in a previous deucrictibant prophylactic study: history of at least 1 attack in the last 3 consecutive months prior to Screening
- Reliable access and ability to use standard of care on-demand treatments to effectively manage acute HAE attacks.

... and 2 more (see full listing online)

Exclusion (13)

- Any diagnosis of angioedema other than HAE
- Participation in a clinical study with any other investigational drug within the last 30 days or within 5 half-lives of the investigational drug at ICF signature (whichever is longer)
- Prior gene therapy for any indication at any time
- Participants who discontinued from previous studies with deucrictibant prophylactic and/or on-demand treatment due to safety reasons or compliance issues that, in the opinion of the Investigator, would interfere with the participant's safety or compliance to participate in the study
- Exposure to ACE inhibitors or any estrogen-containing medications with systemic absorption within 4 weeks of Screening

... and 8 more (see full listing online)

Locations (24 total)

Study Site, Santa Monica, California, United States
Study Site, Walnut Creek, California, United States
Study Site, St Louis, Missouri, United States
... and 21 more locations